Status:
NOT_YET_RECRUITING
Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Lung Neoplasm
Cancer Associated Fibroblast
Eligibility:
All Genders
18+ years
Brief Summary
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. These immunosuppressive mechanis...
Detailed Description
In recent years, immune-based therapies have revolutionized the field of oncology by significantly improving survival of cancer patients. Despite sustained responses, only 20% to 40% of cancer patient...
Eligibility Criteria
Inclusion
- consecutive patients
- lung carcinoma surgically treated by surgery only (objectives 1a and 2), or stage III lung carcinoma treated by concomitant radiochemotherapy followed by durvalumab (maintenance) treated between September 2018 and december 2021 (objective 1b)
Exclusion
- patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
- patient with previous cancer
Key Trial Info
Start Date :
December 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06024538
Start Date
December 1 2025
End Date
December 1 2026
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale
Bordeaux, France, 33000